AT
Amani Therapeutics
United States · Biotech · Healthtech
Biotechnology company developing combination medicines for serious neuropsychiatric disorders.
Developing AM-01 for schizophrenia
Amani Therapeutics develops medicines intended to improve treatment for people living with serious neuropsychiatric disorders. Its lead programme, AM-01, combines clozapine with a novel chemical entity licensed from AstraZeneca.
The company is investigating whether that combination can retain clozapine’s efficacy while reducing severe neutropenia, a reduction in infection-fighting white blood cells, and the associated monitoring burden. AM-01 remains a development programme; those intended benefits require clinical evaluation.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | $25M | RTW Investments — Role not disclosed |